<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499732</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-320</org_study_id>
    <nct_id>NCT01499732</nct_id>
  </id_info>
  <brief_title>Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Compared to Patients With Established RA, and Normal Subjects</brief_title>
  <official_title>An Exploratory Trial to Evaluate Premature Endothelial Dysfunction, as Measured by Positron Emission Tomography (PET) Scan With Cold Pressor Test (CPT), in Patients With Early Rheumatoid Arthritis (RA) Compared to Patients With Established RA, and Normal Subjects. Additionally, the Relationship Between the PET Scan Findings and the Inflammatory, Cardiovascular Risk, and Endothelial Dysfunction Biomarkers Will be Analyzed</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orrin M Troum, M.D. and Medical Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Orrin M Troum, M.D. and Medical Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Premature Endothelial Dysfunction is present in patients with early rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evalute the presence of endothelial dysfunction in patients with rheumatoid arthritis utilizing PET/CT scan with cold pressor test.</measure>
    <time_frame>5 months</time_frame>
    <description>Endothelial dysfunction will be defined as myocardial blood flow (MBF)during cold pressor test (CPT)of less than or equal to 40%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the relationship between PET Scan findings and biomarkers (inflammatory, cardiovascular risk and endothelial dysfunction), and outcome measures</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">15</enrollment>
  <condition>Premature Endothelial Dysfunction</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Early Rheumatoid Arthritis</arm_group_label>
    <description>Subjects currently experiencing active early rheumatoid arthritis (duration of symptoms &lt; or = 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening. Must be drug naive (no prior treatment with traditional disease-modifying antirrheumatic drugs (DMARDs), or biologic response modifying agents)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects without rheumatoid arthritis</arm_group_label>
    <description>Healthy subjects without rheumatoid arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Established Rheumatoid Arthritis</arm_group_label>
    <description>Subjects currently experiencing active established rheumatoid arthritis (duration fo symptoms &gt; or = 2 years) according to the 2010 ACR/EULAR criteria at screening. Subjects with active established RA currently receiving methotrexate, must have received it for at least 12 weeks, and at a stable dose (&gt; or = 15 mg/week) for at least 6 weeks prior to screening. They must be biologic naive, and must recieve at least 5mg oral folic acid weekly</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Five adults (&gt;18 years of age), male or non pregnant, non nursing female with active early
        rheumatoid arthritis (&lt;2 years), five adults, male or non-pregnant, non nursing female with
        active established rheumatoid arthritis (&gt;2 years), and five healthy adults, male or
        non-pregnant, non nursing female without RA are to be enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group 1

          1. Subjects currently experiencing active early RA (duration of symptoms ≤ 2 years)
             according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening.

          2. Subjects with early RA must be drug naïve (no prior treatment with traditional
             disease-modifying antirheumatic drugs (DMARDs), or biologic response modifying
             agents).

             Group 2

          3. Subjects currently experiencing active established RA (duration of symptoms ≥ 2 years)
             according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening.

          4. Subjects with active established RA currently receiving methotrexate (MTX), must have
             received it for at least 12 weeks, and at a stable dose (≥15mg/week) for at least 6
             weeks prior to screening. They must be biologic drug naïve. These subjects must
             receive at least 5 mg oral folic acid weekly.

          5. Subjects diagnosed with RA must be seropositive with documented rheumatoid factor (RF)
             or anti-cyclic citrullinated peptide (anti CCP) positivity. If a documented history of
             RF or anti CCP positivity is not available, RF and anti CCP titers will be obtained at
             screening Group 3

          6. Healthy subjects without RA.

          7. All subjects must have sitting diastolic BP ≤90 mm Hg and/or sitting systolic BP ≤ 140
             at screening

          8. Subjects must have fasting plasma glucose (FPG) of ≤ 100 mg/dL.

          9. If subjects with established RA are receiving an oral corticosteroid, the dose must be
             ≤7 mg/day prednisone (or equivalent) and stable for at least 28 days prior to
             screening.

         10. Subjects able and willing to give written informed consent and comply with the
             requirements of the study protocol. Informed consent must be obtained prior to any
             study-related procedures.

             A copy of the signed informed consent form must be given to the subject

         11. Patients must have a BMI of less than 42

        Exclusion Criteria:

          1. Major surgery (including joint surgery) within 8 weeks prior to screening.

          2. Rheumatic autoimmune disease other than RA, including systemic lupus erythematosus
             (SLE), mixed connective tissue disease (MCTD), scleroderma, polymyositis, or
             significant systemic involvement secondary to RA (vasculitis, pulmonary fibrosis or
             Felty's syndrome). Prior history of or current inflammatory joint disease other than
             RA (gout, Lyme disease, seronegative spondyloarthropathy including reactive arthritis
             and psoriatic arthritis)

          3. Functional class IV as defined by ACR Classification of Functional Status in RA

          4. Current treatment with any traditional DMARDs other than MTX within 4 weeks before the
             screening visit (For subjects with established RA). Current or prior use of
             Leflunomide will be exclusionary.

          5. Treatment with any investigational agent within 4 weeks (or 5 half-lives of
             investigational agent, whichever is longer) before screening

          6. Exposure to any Biologic Response Modifying Agent for RA

          7. Intraarticular or parenteral corticosteroids within 6 weeks prior to screening (For
             subjects with established RA)

          8. Exclusionary laboratory: Serum creatinine &gt;2 mg/dL, ALT or AST &gt; 2.0 x ULN, total
             bilirubin &gt; 2.0 x ULN, platelet count &lt;100 x 10⁹ /L, hemoglobin &lt; 8.5 g/dL, WBC count
             &lt; 1,000/mm³ , absolute neutrophil count &lt; 1,000/ mm³, absolute lymphocyte count &lt;
             500/mm³, triglycerides &gt;400 mg/dL, Serum potassium &lt;3.5 or &gt;5.5 mEq /L without
             medication, serum albumin &lt;2.5 g/dL, Gamma GT 3.0 x UNL

          9. Smokers (use of tobacco products in the recent past &lt; 6 months). Urine cotinine levels
             will be measured during screening for all subjects. Smokers will be defined as any
             subject who reports cigarette use or has a urine cotinine greater than 200 ng/mL.

         10. Pregnant women or nursing mothers

         11. Females of child bearing potential who are not using reliable means of contraception

         12. Evidence of serious uncontrolled concomitant cardiovascular (including known CAD, HTN,
             or hyperlipidemia), nervous system, pulmonary, renal, hepatic, endocrine or GI
             disease.

         13. Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel
             syndrome, where flares are commonly treated with corticosteroids.

         14. History or presence of severe bronchospastic disease (including asthma and chronic
             obstructive pulmonary disease, treated or not treated).

         15. History of cardiovascular abnormalities including myocardial infarction, angina
             pectoris, hypertensive encephalopathy, stroke, transient ischemic attack, valvular
             heart disease, ventricular arrhythmia A-V block, atrial fibrillation or cardiac
             revascularization/angioplasty. Symptoms or clinical evidence of congestive heart
             failure or known left ventricular ejection fraction &lt; 40%.

         16. Medical history of clinically significant ECG abnormalities, including history of a
             prolonged QT-interval syndrome.

         17. History of autonomic dysfunction

         18. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial,
             or other infections such as atypical mycobacterial disease, hepatitis B and C, HIV,
             herpes zoster, or any major episode of infection requiring hospitalization or
             treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2
             weeks prior to screening.

         19. Any malignancy except for skin cancer (basal cell or squamous cell) diagnosed within
             the previous 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orrin M Troum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orrin M. Troum, MD and Medical Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orrin M. Troum, MD and Medical Associates</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <last_update_submitted>May 6, 2013</last_update_submitted>
  <last_update_submitted_qc>May 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Premature endothelial dysfunction</keyword>
  <keyword>Early Rheumatoid Arthritis</keyword>
  <keyword>established rheumatoid arthritis</keyword>
  <keyword>Premature endothelial dysfunction in early rheumatoid arthritis</keyword>
  <keyword>Premature endothelial dysfunction in established rheumatoid arthritis</keyword>
  <keyword>Endothelial function in healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

